CI

At a glance

ClinicalIndex Comparison Record
Phase 2Unknown· 66 target
Drug / intervention
Bevacizumab Injection +2 moredrug
Likely dose
Bevacizumab Injection 15mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03905317
NCT03905317Phase 2Unknown
CompareCT.gov

A Single-Armed Phase II Study of Radiation and Bevacizumab Maintenance Therapy for Oligometastasis of Lung Adenocarcinoma With Negative Driver Gene

Sun Yat-sen University·interventional·Posted Apr 5, 2019·Updated Apr 5, 2019

In Brief

A Phase 2 clinical trial evaluating Bevacizumab Injection, chest radiation, and 1 other intervention for Lung Adenocarcinoma. Targeting 66 participants across 1 site.

Detailed Summary

This prospective phase II study is determined to explore the efficacy and safety of radiotherapy and bevacizumab maintenance therapy for oligometastatic lung adenocarcinoma with negative driver genes

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Adenocarcinoma
CountriesChina
Collaborators--

Timeline

Phase 2UnknownOverdue
20192020202120222023202420252026
First PostedApr 5, 2019
Enrollment StartMar 1, 2019
Primary CompletionFeb 1, 2022
TodayJul 1, 2026
Enrollment to primary: 2.9 yearsPosted 7.2 years ago

Interventions

Bevacizumab Injectiondrug

Bevacizumab maintenance therapy starts 1-2 months later after the chemotherapy.The recommended dose for intravenous infusion is 15mg/kg body weight, and the drug is given every 3 weeks until disease progression or intolerable toxicity occurs.

chest radiationradiation

The patients receive SBRT radiotherapy for the primary (if any) and metastatic lesions or divided radiotherapy with or without concurrent chemotherapy.

concurrent chemotherapydrug

weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡) concurrent with chest radiation